Schizophrenia
📧 Sign up to get email alerts when something new happens for Schizophrenia.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2023-10-10Clinical Trial Update: A Trial of the Efficacy and the Safety of RO6889450 (Ralmitaront) vs Placebo in Patients With an Acute Exacerbation of Schizophrenia or Schizoaffective Disorder [Phase 2]
Phase 2 trial evaluating the efficacy and safety of RO6889450 (ralmitaront) versus placebo in acute exacerbations of schizophrenia or schizo…
-
CLINICAL_TRIALS trial_result · 2023-09-29Clinical Trial Update: Multidisciplinary Design to Optimize Schizophrenia Treatment Based on Multi-omics Data and Systems Biology Analysis [Phase 4]
Phase 4 clinical trial update exploring multidisciplinary design to optimize schizophrenia treatment using multi-omics data and systems biol…
-
FDA approval · 2023-09-25FDA Approved: LYBALVI — Supplemental Application (Alkermes, Inc.)
FDA approved a supplemental application for LYBALVI (olanzapine and samidorphan L-malate) from Alkermes. The action pertains to changes to t…
-
FDA approval · 2023-09-21FDA Approved: PALIPERIDONE — Supplemental Application (NorthStar RxLLC)
FDA approved a supplemental application for paliperidone filed by NorthStar RxLLC under ANDA205618.
-
FDA approval · 2023-09-19FDA Approved: QUETIAPINE FUMARATE — Supplemental Application (Accord Healthcare Inc.)
FDA approves Accord Healthcare's supplemental application to market quetiapine fumarate as a generic drug.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2023-09-18FDA Approved: RISPERIDONE — Supplemental Application (Jubilant Cadista Pharmacuticals Inc.)
FDA approved a supplemental application for risperidone by Jubilant Cadista Pharmaceuticals Inc., updating/expanding its approval for risper…
-
FDA approval · 2023-09-11FDA Approved: FLUPHENAZINE HYDROCHLORIDE — Original Application (Novadoz Pharmaceuticals LLC)
FDA approved an original Abbreviated New Drug Application for fluphenazine hydrochloride by Novadoz Pharmaceuticals LLC, adding a generic op…
-
CLINICAL_TRIALS trial_result · 2023-09-07Clinical Trial Update: The Impact of the COVID-19 (SARS-CoV-2 Disease) on Psychopathology
Clinical trial completed examining the impact of COVID-19 on psychopathology, with results posted in 2023.
-
CLINICAL_TRIALS trial_result · 2023-09-07Clinical Trial Update: Switching From Twice-Daily to Once-Daily Clozapine Dosing in Schizophrenia [Phase 4]
Phase 4 trial update evaluating switching from twice-daily to once-daily clozapine dosing in schizophrenia and schizoaffective disorder.
-
FDA approval · 2023-09-05FDA Approved: PALIPERIDONE — Supplemental Application (Tris Pharma Inc)
FDA granted a supplemental approval for a generic paliperidone product from Tris Pharma Inc (ANDA 212807).
-
CLINICAL_TRIALS trial_result · 2023-09-01Clinical Trial Update: Song-making In a Group (SING) R61 [NA]
Completed results have been posted for the SING (Song-making In a Group) R61 study at Yale, evaluating a group-based intervention for schizo…
-
FDA approval · 2023-08-23FDA Approved: PALIPERIDONE — Original Application (Camber Pharmaceuticals, Inc)
FDA approved Camber Pharmaceuticals' generic paliperidone through original application, enabling a new generic option for this antipsychotic…
-
CLINICAL_TRIALS trial_result · 2023-08-22Clinical Trial Update: Topiramate vs Metformin on Cardio-Metabolic Profile in Schizophrenia on Atypical Antipsychotics [Phase 4]
Phase 4 clinical trial comparing topiramate and metformin on cardio-metabolic outcomes in schizophrenia patients treated with atypical antip…
-
FDA approval · 2023-08-18FDA Approved: FLUPHENAZINE HYDROCHLORIDE — Original Application (Aurobindo Pharma Limited)
FDA approved the Original Application for Fluphenazine hydrochloride from Aurobindo Pharma Limited, granting approval of a generic antipsych…
-
FDA approval · 2023-08-14FDA Approved: CLOZAPINE — Supplemental Application (Aurobindo Pharma Limited)
The FDA approved a supplemental application for clozapine from Aurobindo Pharma Limited, enabling the marketed generic product.
-
FDA approval · 2023-08-08FDA Approved: RISPERIDONE — Supplemental Application (Aurobindo Pharma Limited)
FDA approved a supplemental application for risperidone from Aurobindo Pharma Limited, authorizing a generic risperidone product under ANDA …
-
FDA approval · 2023-08-08FDA Approved: ZIPRASIDONE MESYLATE — Supplemental Application (Fosun Pharma USA Inc.)
FDA approved a supplemental application for ziprasidone mesylate, a salt form of ziprasidone, submitted by Fosun Pharma USA Inc.
-
CLINICAL_TRIALS trial_result · 2023-08-03Clinical Trial Update: Interactions of Fronto-Parietal High Frequency rTMS on Anterior Cingulate Cortex Activation in Schizophrenia [NA]
A completed clinical trial study investigates how high-frequency rTMS over fronto-parietal areas affects anterior cingulate cortex activatio…
-
CLINICAL_TRIALS trial_result · 2023-07-28Clinical Trial Update: rTMS as a Probe of Episodic Memory Neurocircuitry in Schizophrenia [NA]
Completed clinical trial investigating rTMS as a probe of episodic memory neurocircuitry in schizophrenia with results posted in 2023.
-
CLINICAL_TRIALS trial_result · 2023-07-28Clinical Trial Update: Safety, Tolerability, Pharmacokinetics and Efficacy Study of HS-10380 in Patients With Schizophrenia [Phase 1, Phase 2]
Phase 1/Phase 2 clinical trial update for HS-10380 in schizophrenia focusing on safety, tolerability, pharmacokinetics, and efficacy.
-
FDA approval · 2023-07-21FDA Approved: LURASIDONE HYDROCHLORIDE — Supplemental Application (Zydus Pharmaceuticals USA Inc.)
FDA approved a supplemental ANDA for Lurasidone hydrochloride from Zydus Pharmaceuticals USA Inc., enabling the marketing of a generic versi…
-
CLINICAL_TRIALS trial_result · 2023-07-21Clinical Trial Update: Siltuximab in Schizophrenia [Phase 1, Phase 2]
Clinical trial update for siltuximab in schizophrenia exploring Phase 1 and Phase 2 data.
-
CLINICAL_TRIALS trial_result · 2023-07-20Clinical Trial Update: Add-on Aripiprazole on Cardiometabolic Profile in Treatment Resistant Schizophrenia: RCT [Phase 4]
Phase 4 clinical trial evaluating add-on aripiprazole and its effect on cardiometabolic risk in treatment-resistant schizophrenia.
-
FDA approval · 2023-07-17FDA Approved: ARIPIPRAZOLE — Supplemental Application (Ascend Laboratories, LLC)
The FDA approved a supplemental application for aripiprazole from Ascend Laboratories, allowing a generic version to be marketed.
-
CLINICAL_TRIALS trial_result · 2023-07-17Clinical Trial Update: Relapse Prevention Study in Patients With Schizophrenia [Phase 3]
Phase 3 relapse prevention study in schizophrenia has completed; results posted in 2023.